Eosinophilic Granulomatosis with Polyangiitis: From Disease Heterogeneity to Phenotype-Driven Treatment.
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) is a heterogeneous disease in which eosinophilic inflammation, type 2 immunity, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis contribute to varying degrees among individual patients. The introduction of interleukin-5 (IL-5)/IL-5 receptor-targeted therapies, particularly mepolizumab and benralizumab, has transformed EGPA management, enabling substantial glucocorticoid (GC) reduction and making GC-free disease control achievable in selected patients. However, conventional immunosuppression remains important for severe organ-threatening disease, and optimal treatment selection requires consideration of disease severity, organ involvement, eosinophilic versus vasculitic manifestations, relapse pattern, and GC dependency. Major unmet needs include the optimal timing and selection of biologic therapy, strategies for GC withdrawal, and improved definitions of disease activity and remission. This review discusses recent therapeutic advances and proposes a phenotype-driven approach to treatment selection, while highlighting the future transition toward molecular endotyping and precision medicine.